Keith Dawson

1.6k total citations · 1 hit paper
32 papers, 960 citations indexed

About

Keith Dawson is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Keith Dawson has authored 32 papers receiving a total of 960 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pathology and Forensic Medicine, 17 papers in Oncology and 12 papers in Genetics. Recurrent topics in Keith Dawson's work include Lymphoma Diagnosis and Treatment (25 papers), Viral-associated cancers and disorders (14 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Keith Dawson is often cited by papers focused on Lymphoma Diagnosis and Treatment (25 papers), Viral-associated cancers and disorders (14 papers) and Chronic Lymphocytic Leukemia Research (12 papers). Keith Dawson collaborates with scholars based in United States, Switzerland and Belarus. Keith Dawson's co-authors include Jonathan W. Friedberg, Christopher R. Flowers, Brian K. Link, Michelle Byrtek, James R. Cerhan, John D. Hainsworth, Xiaolei Zhou, Andrew D. Zelenetz, Matthew J. Maurer and Charles M. Farber and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Keith Dawson

28 papers receiving 946 citations

Hit Papers

Early Relapse of Follicular Lymphoma After Rituximab Plus... 2015 2026 2018 2022 2015 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
    2015 509 citations Carla Casulo, Michelle Byrtek et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keith Dawson United States 11 841 702 288 210 131 32 960
Michelle Byrtek United States 12 964 1.1× 847 1.2× 316 1.1× 249 1.2× 161 1.2× 29 1.1k
W. Hiddemann Germany 2 871 1.0× 627 0.9× 432 1.5× 94 0.4× 140 1.1× 2 969
Abdulwahab J. Al-Tourah Canada 9 525 0.6× 364 0.5× 189 0.7× 78 0.4× 98 0.7× 18 616
Charles Foussard France 12 885 1.1× 601 0.9× 356 1.2× 74 0.4× 195 1.5× 22 1.0k
Richard H. van der Jagt United States 10 740 0.9× 484 0.7× 504 1.8× 48 0.2× 116 0.9× 19 886
J. Matthews United Kingdom 13 988 1.2× 664 0.9× 428 1.5× 66 0.3× 158 1.2× 20 1.1k
Ulrich von Grünhagen Germany 6 1.2k 1.5× 849 1.2× 789 2.7× 76 0.4× 197 1.5× 10 1.4k
Santiago Mercadal Spain 12 567 0.7× 403 0.6× 235 0.8× 45 0.2× 136 1.0× 56 710
Andrej Vranovský Slovakia 8 675 0.8× 450 0.6× 406 1.4× 58 0.3× 116 0.9× 16 781
Doreen M. Hallman United States 6 583 0.7× 517 0.7× 308 1.1× 60 0.3× 103 0.8× 8 688

Countries citing papers authored by Keith Dawson

Since Specialization
Citations

This map shows the geographic impact of Keith Dawson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Dawson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Dawson more than expected).

Fields of papers citing papers by Keith Dawson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Dawson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Dawson. The network helps show where Keith Dawson may publish in the future.

Co-authorship network of co-authors of Keith Dawson

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Dawson. A scholar is included among the top collaborators of Keith Dawson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Dawson. Keith Dawson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sekulić, Aleksandar, Simon Yoo, Ragini R. Kudchadkar, et al.. (2022). Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry. PLoS ONE. 17(1). e0262151–e0262151. 11 indexed citations
3.
4.
Price, Mark, Arliene Ravelo, Elisa S. Weiss, et al.. (2019). Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: Results from a national patient advocacy survey.. Journal of Clinical Oncology. 37(15_suppl). e18198–e18198. 1 indexed citations
5.
6.
Hanke, C. William, et al.. (2018). Vismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database.. PubMed. 17(2). 143–148. 2 indexed citations
7.
8.
Dawson, Keith, et al.. (2016). Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab. Clinical journal of oncology nursing. 20(2). E41–E48. 10 indexed citations
9.
Nastoupil, Loretta J., Rajni Sinha, Michelle Byrtek, et al.. (2016). Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era. British Journal of Haematology. 172(5). 724–734. 38 indexed citations
10.
Casulo, Carla, Michelle Byrtek, Keith Dawson, et al.. (2015). Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. Journal of Clinical Oncology. 33(23). 2516–2522. 509 indexed citations breakdown →
11.
Nabhan, Chadi, Michelle Byrtek, Ashish Rai, et al.. (2015). Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States. British Journal of Haematology. 170(1). 85–95. 50 indexed citations
12.
Dawson, Keith. (2015). Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States. Journal of Infusion Nursing. 38(Supplement 6S). S4–S10. 1 indexed citations
13.
Casulo, Carla, Bann‐Mo Day, Keith Dawson, et al.. (2015). Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study. Annals of Oncology. 26(11). 2311–2317. 19 indexed citations
14.
Yoo, Simon, Jean Y. Tang, Gary S. Rogers, et al.. (2015). Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study.. Journal of Clinical Oncology. 33(15_suppl). 9022–9022.
15.
Lacouture, Mario E., Jean Y. Tang, Gary S. Rogers, et al.. (2015). The RegiSONIC disease registry: Preliminary effectiveness and safety in the first 66 newly diagnosed locally advanced basal cell carcinoma (BCC) patients treated with vismodegib.. Journal of Clinical Oncology. 33(15_suppl). 9023–9023. 4 indexed citations
16.
Nastoupil, Loretta J., Rajni Sinha, Michelle Byrtek, et al.. (2014). Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leukemia & lymphoma. 56(5). 1295–1302. 17 indexed citations
17.
Nastoupil, Loretta J., Rajni Sinha, Michelle Byrtek, et al.. (2014). The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 120(12). 1830–1837. 23 indexed citations
18.
Dawson, Keith. (2013). Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States. Journal of Infusion Nursing. 36(3). 172–178. 1 indexed citations
19.
Byrtek, Michelle, Xiaolei Zhou, Jonathan W. Friedberg, et al.. (2013). PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study. Blood. 122(21). 4245–4245. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michelle Byrtek Breakdown of academic impact, for papers by W. Hiddemann Breakdown of academic impact, for papers by Abdulwahab J. Al-Tourah Breakdown of academic impact, for papers by Charles Foussard Breakdown of academic impact, for papers by Richard H. van der Jagt Breakdown of academic impact, for papers by J. Matthews Breakdown of academic impact, for papers by Ulrich von Grünhagen Breakdown of academic impact, for papers by Santiago Mercadal Breakdown of academic impact, for papers by Andrej Vranovský Breakdown of academic impact, for papers by Doreen M. Hallman
Rankless by CCL
2026